Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
The latest announcement is out from Prescient Therapeutics Limited ( (AU:PTX) ).
Prescient Therapeutics Limited has announced the issuance of 12,309,738 unquoted equity securities, specifically options expiring on August 31, 2029, with an exercise price of $0.06. This issuance is part of previously announced transactions and reflects the company’s ongoing efforts to strengthen its financial position and support its strategic initiatives in the biotechnology sector.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on the development of targeted therapies for cancer treatment. The company is engaged in advancing its pipeline of innovative cancer drugs to address unmet medical needs in oncology.
Average Trading Volume: 1,303,321
Technical Sentiment Signal: Sell
Current Market Cap: A$43.11M
For an in-depth examination of PTX stock, go to TipRanks’ Overview page.